The influence of treatment intervals on prognosis in young breast cancer patients: Insights from the French National cohort
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Optimizing treatment timing for breast cancer (BC) in young women significantly improves survival. Adhering to specific intervals between surgery, chemotherapy, and radiotherapy reduces recurrence and mortality risks.
Area Of Science
- Oncology
- Clinical Research
- Epidemiology
Background
- Treatment delays negatively impact cancer prognosis.
- Optimal timing for breast cancer (BC) treatment in young women is not well-established.
- This study analyzes treatment delays and their prognostic impact in young BC patients using French nationwide data.
Purpose Of The Study
- To investigate the impact of treatment delays on disease-free survival (DFS) in young women diagnosed with breast cancer.
- To identify optimal time intervals between different treatment modalities (surgery, chemotherapy, radiotherapy) in both adjuvant and neoadjuvant settings.
- To evaluate the association between adherence to an "optimal pathway" and patient outcomes.
Main Methods
- Analysis of the CAREPAT-YBC Cohort from the French National Healthcare System Database.
- Inclusion of 22,093 young women (18-45 years) with breast cancer.
- Assessment of disease-free survival (DFS) based on treatment delays in adjuvant (surgery-chemotherapy-radiotherapy) and neoadjuvant (chemotherapy-surgery-radiotherapy) settings.
Main Results
- Optimal adjuvant chemotherapy-radiotherapy interval identified as 17-31 days; longer delays increased risk.
- Optimal neoadjuvant chemotherapy-surgery interval was 17-31 days; intervals ≤15 days or ≥62 days were associated with poorer prognosis.
- An "optimal pathway" combining best timing reduced the risk of recurrence or mortality by 1.2-fold.
Conclusions
- Optimizing treatment intervals is crucial for enhancing breast cancer survival in younger patients.
- Adherence to specific treatment timelines can significantly improve outcomes for young women with breast cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...